Pneumatosis intestinalis in the pediatric oncology population: An 11‐year retrospective review at Memorial Sloan Kettering Cancer Center

2021 ◽  
Author(s):  
Kayleen A. Bailey ◽  
Hemal Kodikara ◽  
Audrey Mauguen ◽  
Anita Price ◽  
Michael LaQuaglia ◽  
...  
Keyword(s):  
Pediatric Oncology ◽  
Retrospective Review ◽  
Pneumatosis Intestinalis ◽  
Cancer Center

scholarly journals Comparison of Fungal Culture to Surgical Pathology Exam in the Detection of Dimorphic Fungi and the Impact on Treatment and Outcomes: A 25-Year Retrospective Review at a Tertiary Cancer Center

2017 ◽  
Vol 147 (suppl_2) ◽  
pp. S176-S176
Author(s):  
Caitlin Otto ◽  
Darren Buonocore ◽  
Nina Cohen ◽  
Charles Leduc ◽  
Susan Seo ◽  
...  
Keyword(s):  
Retrospective Review ◽  
Surgical Pathology ◽  
Cancer Center ◽  
Fungal Culture ◽  
Dimorphic Fungi ◽  
Impact On Treatment ◽  
The Impact ◽  
Tertiary Cancer Center

Quality of life assessment in pediatric oncology: A retrospective review of phase III reports

1995 ◽  
Vol 41 (10) ◽  
pp. 1463-1465 ◽  
Author(s):  
Andrew S. Bradlyn ◽  
Carole V. Harris ◽  
Leslie E. Spieth
Keyword(s):  
Quality Of Life ◽  
Pediatric Oncology ◽  
Retrospective Review ◽  
Life Assessment ◽  
Phase Iii ◽  
Quality Of Life Assessment

Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2850-2850
Author(s):  
Veena Devi Salem Fauble ◽  
James L Slack ◽  
William Hogan ◽  
Vivek Roy ◽  
Jose Leis ◽  
...  
Keyword(s):  
Stem Cells ◽  
Overall Survival ◽  
Retrospective Review ◽  
Mayo Clinic ◽  
Research Funding ◽  
Graft Failure ◽  
Clinical Course ◽  
Cancer Center ◽  
Blast Phase ◽  
Graft Versus Host

Abstract Abstract 2850 Myelofibrosis (MF), both primary myelofibrosis (PMF) and post essential thrombocytosis/polycythemia vera myelofibrosis (post ET/PV-MF), are chronic myeloproliferative neoplasms characterized by a progressive clinical course that leads to shortened survival. The heterogeneous nature of MF lends itself to a variable clinical course that commonly includes hepatosplenomegaly, constitutional symptoms, and progressive cytopenias. Medical therapy for myelofibrosis has been effective in palliation of common symptoms related to anemia, splenomegaly but allogeneic stem cell transplantation (ASCT) remains the only potentially curative therapeutic modality. The timing of ASCT, choice of conditioning regimen, patient selection and the impact of co-morbidities are critical to optimal use of this modality. We have retrospectively analyzed our experience for patients undergoing ASCT for primary and post ET/PV myelofibrosis at Mayo Clinic across all 3 sites: Scottsdale Arizona; Rochester, Minnesota; and Jacksonville, Florida. Methods: We conducted a retrospective review of all patients from 1992 to 2012 with PMF or post ET/PV-MF who underwent an ASCT at Mayo Clinic. This retrospective review included a waiver of informed consent and was approved by the Mayo Clinic Institutional Review Board. Patients that transformed to the MPN blast phase and individuals who underwent a second transplant for either relapse or graft failure were also included. Overall survival was estimated using Kaplan-Meier. Associations between prognostic factors and overall survival were assessed using Cox regression. Results: Baseline Patient Characteristics: Forty-eight patients (29 male) with a median age of 57 yrs (range 31–73) underwent ASCT. DIPSS-plus risk score was low in 2, intermediate 1 in 2, intermediate 2 in 9 and high in 35 patients. Disease type was PMF in 24, PV-MF in 10, ET-MF in 10, and MPN/MDS overlap in 4 pts. Eight patients evolved to the MPN-blast phase prior to transplant. JAK-2 mutation was positive in 27 patients and negative in 12 patients with JAK-2 status unknown in 9 patients. The median time from PV/ET to MF was 136 months (83–189 months) and from MF diagnosis to transplant was 59 months (3–144 months). All but 2 patients were red cell transfusion dependent prior to transplant (96%). Eight patients underwent splenectomy prior to transplant. Transplantation Characteristics: Patients who underwent ASCT received either myeloablative (MA, 13 pts) or reduced-intensity conditioning (RIC, 35 pts) regimen. The graft was from an unrelated donor in 22 pts and related donor in 26 pts with 44 being matched and 4 being mismatched. The myeloablative regimens included Bu/Cy, TBI/Cy, and Bu/Flu. The RIC regimens included flu/mel, Bu/Flu, FBM, and TBI/Flu. GVHD prophylaxis was with tacrolimus/MTX, CSA/MTX, and tacrolimus/MMF. Nineteen patients received ATG. Infectious disease prophylaxis, CMV monitoring, and additional supportive care measures were according to institutional guidelines. A majority of patients received peripheral blood stem cells with only 1 patient receiving bone marrow as the source of stem cells. Outcomes: The median time to neutrophil engraftment was 17.2 days. Two patients received a second transplant for relapsed disease. The incidence of graft failure was 10%. Graft versus host disease both acute and chronic occurred in 33 patients and 15 patients respectively. Day 100 overall survival was 92% and 2 year survival was 62% (95% CI 45–75%). There were no statistically significant associations between individual prognostic factors (DIPSS-plus classification, age, and HLA match) and survival. Conclusions: The Mayo Clinic national experience of ASCT for MF across our geographically diverse Cancer Center is encouraging. Our centers have transplanted 48 patients over the past 10 years with very favorable outcomes. Our results from a multi center practice are consistent with regards to survival, graft versus host disease, and types of transplants being performed compared to currently available published data from large single location transplant centers. This data helps confirm the prevailing knowledge that ASCT is a useful treatment. Disclosures: Mesa: Incyte: Research Funding; Lilly: Research Funding; Sanofi: Research Funding; NS Pharma: Research Funding; YM Bioscience: Research Funding.

Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4545-4545 ◽  
Author(s):  
T. R. Asmis ◽  
M. N. Reaume ◽  
S. Dahrouge ◽  
S. Malone
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Retrospective Review ◽  
Small Cell ◽  
Cancer Center ◽  
Survival Patterns

Safety and efficacy of pegfilgrastim in pediatric oncology patients: The M.D. Anderson Cancer Center experience

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 8272-8272
Author(s):  
S. E. Koontz ◽  
L. R. Mohassel ◽  
N. Jaffe ◽  
M. Pearson ◽  
C. Herzog ◽  
...  
Keyword(s):  
Pediatric Oncology ◽  
Cancer Center ◽  
Oncology Patients ◽  
Safety And Efficacy

Improving transitions of care through implementation of a standardized handoff at a comprehensive cancer center.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 242-242
Author(s):  
Diane C. Bodurka ◽  
Mohamed Ait Aiss ◽  
Helene P Phu ◽  
Lakeisha R Day ◽  
Varkey Abraham ◽  
...  
Keyword(s):  
Pediatric Oncology ◽  
Medical Errors ◽  
Gynecologic Oncology ◽  
Skills Training ◽  
Illness Severity ◽  
Transitions Of Care ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Post Intervention

242 Background: Communication failures cause two-thirds of sentinel events in hospitals. These adverse occurrences are often both fatal and preventable. Consequently, improving the quality of handoffs has been identified by multiple accreditation constituents as a top priority patient safety goal. This project was part of an institutional initiative to standardize handoffs among physicians, trainees, and midlevel providers. Methods: Four subgroups were identified as pilot areas: Gynecologic Oncology (Gyn Onc) fellows to nocturnalists, Surgical Oncology fellows, Pediatric Oncology residents and fellows, and Emergency Center attending staff to inpatient hospitalists. This abstract focuses on the Gyn Onc and Pediatric Oncology services. All teams used a PDSA cycle (Plan, Do, Study, Act) to conduct its pilot study. A gap analysis, root cause analysis, and process mapping were performed in each area to identify specific handoff issues. A validated standardized handoff tool, I-PASS (Illness severity, Patient summary, Action list, Situational awareness and contingency planning, and Synthesis by receiver), was selected. Of note, “Illness severity” highlights patients identified at higher risk for complications and denotes their status as “watcher” or “unstable.” Interventions included I-PASS skills training and utilization of the I-PASS mnemonic. Each service developed a standardized definition to identify patients classified as “watchers.” Medical errors, ICU transfers, and provider satisfaction were assessed pre- and post-intervention. Results: Results from 40 handoff surveys showed communication errors dropped by 10% (16.49 vs 14.93). Minor harm as result of a problematic handoff decreased by 45% (2.55 vs 1.39), with a 55% reduction in ICU transfers. There was an overall increase in handoff satisfaction using I-PASS and 100% standardization of handoffs across the Gyn Onc and Pediatric Oncology units. Conclusions: Implementation of I-PASS, a validated standardized handoff was associated with reductions in medical errors and improvement in communication. Our institution is moving toward implementing I-PASS across all units to increase the safety and quality of patient care.

scholarly journals Small Cell Cancer of the Bladder and Prostate: A Retrospective Review from a Tertiary Cancer Center

Cureus ◽  
2015 ◽  
Author(s):  
Shahida Ahmed ◽  
Sam Neufeld ◽  
Tadeusz J Kroczak ◽  
Bashir Bashir ◽  
Naseer Ahmed ◽  
...  
Keyword(s):  
Retrospective Review ◽  
Cell Cancer ◽  
Small Cell ◽  
Cancer Center ◽  
Small Cell Cancer ◽  
Cancer Of The Bladder ◽  
Tertiary Cancer Center

Retrospective review of immune checkpoint inhibitor therapy (ICI) at the Michael E. DeBakey VA Medical Center Cancer Center (MEDVAMCCC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e15091-e15091
Author(s):  
Jan Ole Kemnade ◽  
Nan Chen ◽  
John Mbue ◽  
Rosetta Lee ◽  
Cheng-Yen Chang ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Retrospective Review ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Medical Center ◽  
Inhibitor Therapy ◽  
Cancer Center ◽  
Checkpoint Inhibitor Therapy
Sign in / Sign up

Export Citation Format

Share Document